It also looks like Abbott is being aggressive about moving the uterine fibroids drug forward. They have good reason to believe that this one will also be successful because they already have good data on the ability to reduce bleeding.
The market has recently killed this stock and many many other smallcap biotechs. With the stock rebound expected today, along with the very promising words from the Deutsche Bank conference, I am expecting a healthy recovery starting today. We will see.
You got that right! The solvency issues in Europe are killing the market. With Abbott releasing the clinical trial design on clinicaltrials.gov sometime within the 3 or 4 days, we have a chance to get some more new interest in the stock. It would be from people who follow Abbott instead of NBIX.
NBIX has plenty of cash and a maturing pipeline, so we can wait it out and let the results speak for themselves. It just should be worth so much more than it is now.